Juniper Networks is collaborating with a range of charitable organizations to provoke change in the world through a diverse set of interests. Juniper is investing in STEM education initiatives to empower girls and underprivileged youth populations in local schools. Juniper has partnered with several organizations to help advance these efforts, including Girlstart, Hidden Genius Project, and Project Learn.

Additionally, Juniper has put forth robust relief efforts in response to natural disasters to help communities rebuild and revitalize. Since 2015, the company has donated more than $1 million to support relief efforts worldwide. Juniper also emphasizes the importance of volunteering to help support the communities it’s connected to. That’s why every full-time employee is entitled to five paid working days a year that can be spent volunteering for a cause they’re passionate about. Through Juniper’s Matching Gift Program, the company matches donations up to $1000 per year, per employee.

“From STEM education to disaster relief and community volunteering, we partner with charitable organizations whose values align with ours to power connections and empower change in the world.”

You can read more about Juniper Network’s work here.

Twilio believes that when people have access to the information and resources they need, they can take action to improve their outcomes and long-term wellbeing. That’s why the company worked to drive better outcomes across the vaccine lifecycle.

Twilio contributed $10 million to Gavi, the Vaccine Alliance that supports COVAX, an initiative to provide vaccines to low and middle-income countries. Twilio grantees and customers are also using on-the-ground expertise and technology to solve complex distribution challenges and the company is also partnering with organizations to build vaccine understanding and confidence. Finally, many organizations are using Twilio to connect to people directly and increase vaccination rates by communicating availability, booking appointments and delivering reminders about subsequent shots. 

“For me, Twilio has been THE stand-out technology company that has really put action behind words to support vaccine equity. The company has not only led through substantive funding but equally through the team’s energy, creativity and sheer dedication to get a product to market that actually aims to change things for the future.”

You can read more about Twilio’s work here.

IBM is in a unique position to uncover new insights to address the opioid epidemic. Its Science for Good program focuses on analyzing the relationship between factors surrounding an initial opioid prescription and a subsequent diagnosis of addiction. The goal is to identify causal (and not merely correlated) factors that lead to an addiction diagnosis. 

IBM’s work represents the beginning of a long and potentially far-reaching mission to make inferences about undiagnosed individuals in order to offer guidelines on opioid prescriptions.

“Overall, our vision is to draw upon the richness of IBM’s claims and other healthcare data to deliver insights tailored to the needs of different stakeholders. With an epidemic of this magnitude, such joint efforts are clearly needed.”

You can read more about IBM’s work here.

In today’s fast-paced world, demonstrations of “the art of the possible,” combined with advanced digitalization and factory automation, are one way Siemens showcases how different processes and technologies can help prepare for potentially disruptive changes to design and production norms. This preparation and understanding can lead to more rapid responses to pandemics, such as the COVID-19 virus, as well as enhance our ability to respond to future emerging threats.

To support the FDA’s Office of Counterterrorism and Emerging Threats (OCET) advanced manufacturing program, Siemens will install and configure an advanced digital design and manufacturing showcase to demonstrate “the art of the possible” in creating digital twins and digital threads for some medical devices. This will include an actual manufacturing line with Siemens Digital Industries Software’s Xcelerator portfolio, including advanced integrated software capabilities for design control and risk management; product lifecycle management; product, plant, and process design modeling and simulation; manufacturing execution; closed-loop quality management; Industrial Internet of Things (IIoT) and much more. This advanced digital technology is already used in many industries, including aerospace, defense, automotive, and consumer products.

Creating and leveraging digital threads are an invaluable capability for both medical device manufacturers and the FDA. Digital twins and threads, with the use of integrated advanced modeling and simulation, can enable significantly better product design and performance with more optimized production. Digital artifacts can be reused across the lifecycle, creating efficiency, fewer mistakes, and increased quality. This capability can also help regulators better visualize product and manufacturing risks, provide more robust traceability and impact analysis, and enable more comprehensive data sets that are easier and faster to review. In summary, regulators will be able to respond much faster with more precision and with better information to both emergency and non-emergency needs.

Siemens’ long-term goal for this project is to use technology to help educate and drive digital thread adoption for both the manufacturers and regulators. That can lead to better patient outcomes and a more efficient and competitive industry.